{
  "abstract": "In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m2, ≥35 to <40 kg/m2, and ≥40 kg/m2) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates. Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620.",
  "abstract_shown": true,
  "affiliations": [
    "Knownwell, San Diego, CA, USA.",
    "Louisville Metabolic and Atherosclerosis Research Center, Monroe Biomedical Research, Louisville, KY, USA.",
    "University College Dublin, Belfield, Dublin, Ireland.",
    "Ulster University, Coleraine, UK.",
    "Eli Lilly and Company, Indianapolis, IN, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Michelle Look"
    },
    {
      "affs": [
        1
      ],
      "name": "Harold Bays"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Carel W Le Roux"
    },
    {
      "affs": [
        4
      ],
      "name": "Neena A Xavier"
    },
    {
      "affs": [
        4
      ],
      "name": "Sheryl Elaine Allen"
    },
    {
      "affs": [
        4
      ],
      "name": "Irina Jouravskaya"
    },
    {
      "affs": [
        4
      ],
      "name": "Adam Stefanski"
    },
    {
      "affs": [
        4
      ],
      "name": "Georgios K Dimitriadis"
    },
    {
      "affs": [
        4
      ],
      "name": "Benjamin Behrend"
    },
    {
      "affs": [
        4
      ],
      "name": "Wenyu Ye"
    },
    {
      "affs": [
        4
      ],
      "name": "Jinhong Li"
    },
    {
      "affs": [
        4
      ],
      "name": "Theresa Hunter Gibble"
    },
    {
      "affs": [
        4
      ],
      "name": "Christy Houle"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/36m23yvvmc5hd.bib",
  "cited_by": 0,
  "doi": "10.1016/j.obpill.2026.100347",
  "fulltext_url": "https://europepmc.org/articles/PMC13743930",
  "id": "36m23yvvmc5hd",
  "issns": [
    "2667-3681"
  ],
  "landing_url": "https://europepmc.org/article/MED/42999545",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2736|Pharmacology and Obesity Treatment"
    ]
  ],
  "openalex": "W7221725043",
  "pdf_url": "https://europepmc.org/articles/PMC13743930?pdf=render",
  "pmcid": "PMC13743930",
  "pmid": "42999545",
  "published": "2026-10-13",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/36m23yvvmc5hd.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:41Z",
      "native_id": "MED:42999545",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42999545"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2736|Pharmacology and Obesity Treatment",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.",
  "title_text": "Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:41Z",
  "url": "https://research.draconitic.com/paper/36m23yvvmc5hd",
  "venue": "Obesity pillars",
  "versions": []
}